Disseminated Cryptococcosis in a Patient with Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone
| Autor: | Shuku Sato, Yotaro Tamai, Emiko Kambe |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
cryptococcosis Opportunistic infection disseminated cryptococcosis Antineoplastic Agents Case Report Opportunistic Infections 030204 cardiovascular system & hematology Gastroenterology Dexamethasone 03 medical and health sciences Lethargy Fatal Outcome 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols Internal Medicine medicine Humans Letters to the Editor Lenalidomide Multiple myeloma Bortezomib business.industry Antibodies Monoclonal HIV Daratumumab General Medicine Middle Aged lymphopenia medicine.disease daratumumab Cryptococcosis Cryptococcus neoformans Female 030211 gastroenterology & hepatology Multiple Myeloma business medicine.drug |
| Zdroj: | Internal Medicine |
| ISSN: | 1349-7235 0918-2918 |
| Popis: | We report a case of disseminated cryptococcosis in a patient with multiple myeloma (MM) during treatment with daratumumab, lenalidomide, and dexamethasone (DRd). A 62-year-old woman, who was diagnosed with IgGλ type MM, was treated with three cycles of bortezomib and dexamethasone and subsequently treated with three cycles of DRd before admission. She reached a stringent complete response and presented with lethargy and seizure. Laboratory findings revealed severe CD4 lymphopenia, and Cryptococcus neoformans was detected in her cerebrospinal fluid and blood culture. The risk of developing an opportunistic infection should be considered in patients treated with daratumumab. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|